Breast and prostate cancer are among the most commonly diagnosed cancers worldwide. Recent advances in tumor sequencing and gene studies have led to a paradigm shift from treatment centered on the type of tumor to therapy more focused on specific immune phenotype markers and molecular alterations. In this review, we discuss the utility and function of talazoparib concerning prostate cancer treatment and summarize recent and planned clinical trials on talazoparib. We searched medical databases for articles relating to the use of talazoparib in prostate cancer from inception. Poly ADP ribose polymerase (PARP) is a family of 17 necessary DNA repair enzymes responsible for base excision repair, single-strand break repair, and double-strand break repair. PARP inhibitors are a class of oral targeted therapies that compete for the NAD + binding site on PARP molecules. Talazoparib, a potent PARP inhibitor, has emerged as a significant therapeutic option in the treatment of metastatic castration-resistant prostate cancer (mCRPC), particularly for patients with specific genetic alterations. Its role as a PARP inhibitor makes it a targeted therapy, focusing on cancer cells with DNA repair deficiencies. Talazoparib’s role as a biomarker-directed therapy in advanced prostate cancer has been increasingly recognized. The TALAPRO-1 demonstrated durable antitumor activity in mCRPC patients. TALAPRO-2 is a notable clinical trial, specifically examining the effectiveness of Talazoparib when used in combination therapies. Current investigations demonstrate a significant improvement in survival outcomes for the patients of mCRPC, making Talazoparib a promising intervention.

Zaheer Qureshi

Eeshal Fatima

Adnan Safi

Mikail Khanzada

Faryal Altaf

American Journal of Clinical Oncology

​​​​​​​American Journal of Clinical Oncology is a multidisciplinary journal for cancer surgeons, radiation oncologists, medical oncologists, GYN oncologists, and pediatric oncologists.

The emphasis of AJCO is on combined modality multidisciplinary loco-regional management of cancer. The journal also gives emphasis to translational research, outcome studies, and cost utility analyses, and includes opinion pieces and review articles.

The editorial board includes a large number of distinguished surgeons, radiation oncologists, medical oncologists, GYN oncologists, pediatric oncologists, and others who are internationally recognized for expertise in their fields.

The American Journal of Clinical Oncology: Cancer Clinical Trials is a multidisciplinary journal aimed at cancer surgeons, radiation oncologists, medical oncologists, GYN oncologists, and pediatric oncologists. The journal emphasizes combined modality multidisciplinary loco-regional management of cancer. It also focuses on translational research, outcome studies, and cost utility analyses, and includes opinion pieces and review articles. The editorial board consists of a large number of distinguished surgeons, radiation oncologists, medical oncologists, GYN oncologists, pediatric oncologists, and others who are internationally recognized for their expertise in their fields.

《American Journal of Clinical Oncology: Cancer Clinical Trials》是一本多学科期刊，面向癌症外科医生、放射肿瘤学家、内科肿瘤学家、妇科肿瘤学家和儿科肿瘤学家。期刊重点关注癌症的综合性多学科局部管理，同时也强调转化研究、结果研究和成本效用分析，并包含意见文章和综述文章。编辑委员会由众多在各自领域享有国际声誉的杰出外科医生、放射肿瘤学家、内科肿瘤学家、妇科肿瘤学家、儿科肿瘤学家等组成。

Category	Quartile
医学	4
医学, 肿瘤学	4

Talazoparib for the Treatment of Metastatic Castration-resistant Prostate Cancer

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info